Study: NCT03631199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: canakinumab-matching placebo
Description: canakinumab placebo every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 every 3 weeks (non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 every 3 weeks (non-squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: 75 mg/m\^2 every 3 weeks (non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m\^2 every 3 weeks (squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m\^2 every 3 weeks (squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Description: 200 mg/m\^2 every 3 weeks (squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 every 3 weeks (non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 every 3 weeks (non-squamous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 every 3 weeks (non-squamous)

Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed
Description: 500 mg/m\^2 every 3 weeks (non-squamous)